An observational study in Epileptic Seizures, sponsored by University Hospital, Basel, Switzerland. Recruiting at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by University Hospital, Basel, Switzerland · Observational
The aim of this observational multicenter cohort study is to gain a deeper understanding regarding the effects of treatment adaption based on information from outcome prediction models, risk stratification, as well as treatment monitoring, detection, prevention, and management of complications on course and outcome of adult patients with status epilepticus (SE).
124 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 156 across 42 observational studies indexed under Status Epilepticus.
Browse Status Epilepticus studies →University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.
Compared within Status Epilepticus, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Seizures. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Adult patients (i.e., patients ≥18 years of age) with SE treated at the University Hospital Basel and the Cantonal Hospital Aarau.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: collection of patient data
Extract data from the digital medical records, the electroencephalographic and microbiologic database.
Demographics
age, sex
Time frame: between 01.01.2005 and 31.12.2023
Data from acute prehospital management by the emergency medical services (EMS)
extracted from the treatment protocols of the EMS
Time frame: between 01.01.2005 and 31.12.2023
Duration of ICU (intensive care unit) and hospital stay, and destination at discharge
Duration of ICU (intensive care unit) and hospital stay, and destination at discharge
Time frame: between 01.01.2005 and 31.12.2023
Date(s) of seizure(s) captured by electroencephalographic (EEG) data
Date(s) of seizure(s) captured by EEG
Time frame: between 01.01.2005 and 31.12.2023
Seizure history and etiology
withdrawal from anti seizure drugs, structural, infectious, or autoimmune causes
Time frame: between 01.01.2005 and 31.12.2023
Number and Duration of SE episodes
Number and Duration (time) of SE episodes
Time frame: between 01.01.2005 and 31.12.2023
Types of SE
Types of SE according to the current guidelines from the International League of Epilepsy (ILAE) (i.e., nonconvulsive with coma, SE with motor symptoms, focal nonconvulsive SE without coma, and subtle SE
Time frame: between 01.01.2005 and 31.12.2023
Additional features of the seizure
length, level of consciousness at onset, previous epileptic seizures
Time frame: between 01.01.2005 and 31.12.2023
ICU Scoring Systems
Critical illness severity scores (e.g., acute physiology and chronic health Evaluation (APACHE II), simplified acute physiology score (SAPS II), sequential organ failure assessment (SOFA), etc.)
Time frame: between 01.01.2005 and 31.12.2023
Clinical neurologic monitoring scores
Clinical neurologic monitoring scores (e.g., Richmond Agitation-Sedation Scale (RASS) , Seda-tion-Agitation Scale (SAS), Glasgow Coma Score (GCS), Intensive Care Delirium Screening Checklist (ICDSC), Status Epilepticus Severity Score (STESS))
Time frame: between 01.01.2005 and 31.12.2023
Laboratory parameters
C-Reactive Protein (CRP), albumin, Lactate Dehydrogenase (LDH), Creatin-Kinase (CK), procalcitonin, white blood cell levels, creatinine, liver enzymes, blood gas analyses, metabolic data
Time frame: between 01.01.2005 and 31.12.2023
Outcome measure
in-hospital death, survival, survival with neurofunctional alteration, Glasgow Outcome Score, return to neurofunctional premorbid baseline, readmission
Time frame: between 01.01.2005 and 31.12.2023
Therapeutic features
duration, dosage and number of treatment medication, number of antiseizure drugs, invasive procedures, such as intubation, mechanical, ventilation, vasopressors, installation of central lines, nutrition
Time frame: between 01.01.2005 and 31.12.2023
Monitoring of vital signs
blood pressure, heart rate, respiratory rate, oxygen saturation of the blood, body temperature, level of consciousness
Time frame: between 01.01.2005 and 31.12.2023
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland →